124I-evuzamitide Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 26, 2026

The clinical evidence base for 124I-evuzamitide comprises 3 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Amyloid Neuropathies, Familial, and Amyloidosis, Hereditary, Transthyretin-Related. Most recent publication: Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography., JACC Cardiovasc Imaging, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography.
Smiley DA, Einstein AJ, O'Gorman KJ, et al. · JACC Cardiovasc Imaging · 2025
PubMed: PMID 40439628 · NCT05635045 · Amyloidosis, Hereditary, Transthyretin-Related
Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study.
Wall JS, Martin EB, Lands R, et al. · JACC Cardiovasc Imaging · 2023
PubMed: PMID 37940323 · NCT06788535 (REVEAL) · Amyloid Neuropathies, Familial
Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study.
Clerc OF, Cuddy SAM, Robertson M, et al. · JACC Cardiovasc Imaging · 2023
PubMed: PMID 37676210 · NCT06788535 (REVEAL) · Amyloid Neuropathies, Familial

Publications by year

2023–2025: 3 publications.

2023

2025

Publications by indication

Amyloid Neuropathies, Familial (2)

Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study.
JACC Cardiovasc Imaging · 2023 · PMID 37940323 · NCT06788535
Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study.
JACC Cardiovasc Imaging · 2023 · PMID 37676210 · NCT06788535

Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography.
JACC Cardiovasc Imaging · 2025 · PMID 40439628 · NCT05635045

Publications by journal

JACC Cardiovasc Imaging3 papers

All 124I-evuzamitide publications (3)

2025 (1 paper)

Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography.
Smiley DA, Einstein AJ, O'Gorman KJ, et al. · JACC Cardiovasc Imaging · 2025 · Derived
PubMed: PMID 40439628 · NCT05635045 · Amyloidosis, Hereditary, Transthyretin-Related

2023 (2 papers)

Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study.
Wall JS, Martin EB, Lands R, et al. · JACC Cardiovasc Imaging · 2023 · Background
PubMed: PMID 37940323 · NCT06788535 (REVEAL) · Amyloid Neuropathies, Familial
Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study.
Clerc OF, Cuddy SAM, Robertson M, et al. · JACC Cardiovasc Imaging · 2023 · Background
PubMed: PMID 37676210 · NCT06788535 (REVEAL) · Amyloid Neuropathies, Familial

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 26 May 2026 18:15:31 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).